Résumé
There is still a need for better protection against or mitigation of the effects of ionizing radiation following conventional radiotherapy or accidental exposure. The objective of our current study was to investigate the possible roles of matrix metalloproteinase inhibitor, ilomastat, in the protection of mice from total body radiation (TBI), and the underlying protective mechanisms. Ilomastat treatment increased the survival of mice after TBI. Ilomastat pretreatment promoted recovery of hematological and immunological cells in mice after 6 Gy γ-ray TBI. Our findings suggest the potential of ilomastat to protect against or mitigate the effects of radiation.
Sujets)
Animaux , Souris , Syndrome d'irradiation aigu , Sang , Allergie et immunologie , Cellules sanguines , Effets des rayonnements , Relation dose-effet des médicaments , Rayons gamma , Acides hydroxamiques , Utilisations thérapeutiques , Indoles , Utilisations thérapeutiques , Inhibiteurs de métalloprotéinases matricielles , Utilisations thérapeutiques , Lésions radiques expérimentales , Sang , Allergie et immunologie , Radioprotecteurs , Utilisations thérapeutiques , Rate , Allergie et immunologie , Effets des rayonnements , Analyse de survie , Irradiation corporelle totaleRésumé
<p><b>OBJECTIVE</b>To establish of acute respiratory distress syndrome (ARDS) model in canine after inhalation of perfluoroisobutylene (PFIB), and to observe the progressing of lung injury, and to study the mechanisms of injury.</p><p><b>METHODS</b>A device of inhalation of PFIB for canine was made. The concentration of PFIB was 0.30 - 0.32 mg/L. Serum IL-6 and IL-8 were dynamically measured. Clinical manifestations, pathology of organs in canine were observed.</p><p><b>RESULTS</b>(1) During inhalation, the concentration of PFIB remained stable; (2) After inhalation, blood arterial oxygen partial pressure fell gradually, and eventually met the criteria for diagnosing ARDS; (3) The level of IL-8 in serum rises significantly after inhalation (P < 0.05), whereas that of IL-6 was not obviously altered (P > 0.05); (4) Within 6 hours after inhalation, no abnormality in canine was observed, but afterwards symptoms gradually appeared, and typical breath of ARDS, such as high frequency and lower level could be seen in later phase; (5) Pathological examination showed severe congestion, edema and atelectasis in most part of both lungs, and signs of anoxia in other organs.</p><p><b>CONCLUSIONS</b>(1) The device designed is capable of ensuring control of inhalation of PFIB; (2) Exposure to PFIB for 30 mins, canines all met the criteria for diagnosing ARDS 22 hours after inhalation, therefore the modeling is successful; (3) PFIB specifically damages the lung by causing excessive inflammation.</p>